Skip to main content

Sources last read

The page

Ozempic patch: what Novo Nordisk actually makes

There is no Ozempic patch. Ozempic is application NDA 209637, approved to Novo Nordisk on 2017-12-05, and every product under it is an injection under the skin. The same holds for Wegovy, Mounjaro and Zepbound. A listing selling an “Ozempic patch” is not selling anything Novo Nordisk makes.

Source: Drugs@FDA application records, checked 2026-08-13

What matters first

Ozempic patch
Does not exist
Approved form
Injection under the skin
Application
NDA 209637
Manufacturer
Novo Nordisk

This matters more than the wording suggests. Ozempic is a brand name owned by one company, and that company files everything it sells with the FDA. So the question “is there an Ozempic patch” has a documentary answer rather than an opinion: you look up the application and read the list of forms.

Every form the four big brands come in

Four brands, two molecules, two companies. Each row is read from that product’s own FDA application and label. There is one non-injected form in the whole table, and it is a tablet you swallow.

BrandMoleculeApplicationFirst approvedHow it goes inPatch
WegovySemaglutideNDA 2152562021-06-04Injection under the skin, and a tablet you swallowNone
OzempicSemaglutideNDA 2096372017-12-05Injection under the skinNone
ZepboundTirzepatideNDA 2178062023-11-08Injection under the skinNone
MounjaroTirzepatideNDA 2158662022-05-13Injection under the skinNone
TrulicityDulaglutideBLA 1254692014-09-18Injection under the skinNone
VictozaLiraglutideNDA 0223412010-01-25Injection under the skinNone
SaxendaLiraglutideNDA 2063212014-12-23Injection under the skinNone
RybelsusSemaglutideNDA 2130512019-09-20Injection under the skinNone

Application numbers and approval dates come from the signed FDA approval letter for each product. The full schedules are on each brand’s own page.

2Read beyond the approved formsThe real needle-free option and what patch listings are actually selling

The needle-free option that does exist

If you are searching for a patch because you would rather not inject, there is a real answer, and it is not a patch. Semaglutide comes as a tablet. Wegovy tablets won approval on 2025-12-22 under application NDA 218316, and they cover two of the four things the Wegovy shot covers. Rybelsus is the older tablet, approved for type 2 diabetes.

That is worth separating from everything else on this page. Semaglutide does not cross skin. It does cross the stomach lining, badly, and a dedicated helper ingredient was built to make that happen. “Not absorbed through skin” and “injection only” are two different statements, and only the first one is true.

The dosing for both tablets is on the Wegovy record, read from the label rather than summarized from a press release.

So what is an “Ozempic patch” listing selling?

One of two things, and they are not related to each other. Most are stickers carrying plant extracts, usually berberine, sold as supplements. Several of those listings state plainly that the product holds no GLP-1 drug at all. A smaller group describes itself as a microneedle patch and says it contains semaglutide or tirzepatide — 4 of the listings we read make that claim, none publishes an ingredient list, and the FDA has written to a seller of one calling it an unapproved new drug.

Either way, the brand name on the search box is doing work the product cannot. We read every listing we could find and wrote down what each one says in the patch brand register.

Searches for a “tirzepatide patch” or a “semaglutide patch” land in exactly the same place. Tirzepatide has no registered trial of skin delivery anywhere in the world, so there is even less behind that name than behind the semaglutide one.

What remains unknown

  • Drugs@FDA lists products FDA has approved. It says nothing about what is sold without approval, which is the category every patch on the market falls into.
  • Approval records change. Each row carries the application it came from so you can re-read it, and a new form would show up there before it showed up here.
  • A tablet is a different product with its own dose schedule and label. Only a prescriber can decide whether it suits a particular person.
  • This page is about brand names and approved forms. Whether a patch could ever work is a research question, and the microneedle record covers it separately.

Questions people actually ask

Does Novo Nordisk make an Ozempic patch?

No. Application NDA 209637 covers pens and prefilled syringes, all injected under the skin. Novo Nordisk has no approved patch of any kind for semaglutide, and no registered trial of one under its own name.

Is there a Mounjaro or Zepbound patch?

No. Both are tirzepatide, both from Eli Lilly, and both are injections only. Tirzepatide is the heavier of the two GLP-1 molecules and has no registered human trial of delivery through skin at all.

How much does an Ozempic patch cost?

There is no such product, so any price you see belongs to something else — usually a berberine sticker between about $12 and $40 a month. Real Ozempic pricing is a different question, and the cost records cover it with the manufacturer terms and their exclusions.

Are the patches sold as Ozempic patches safe?

Unknown. Most sellers publish no ingredient list. FDA’s drug side-effect database holds no report naming any of them, which sounds reassuring and is not: that database is fed by prescribers and drug manufacturers, and none of them are involved in an online patch sale.

What can I take instead if I do not want injections?

Semaglutide tablets exist and are approved, which is a real answer to the question the patch searches are asking. Which product suits anyone is a prescriber’s call — this site records what is approved and never recommends a treatment or a dose.

Sources

  1. Drugs@FDA: FDA-Approved Drugs — queried through the openFDA drug/drugsfda endpoint · U.S. Food and Drug Administration · retrieved 2026-08-12
  2. Drugs@FDA: FDA-Approved Drugs (search interface) · U.S. Food and Drug Administration · retrieved 2026-08-12
  3. WEGOVY (semaglutide) injection and tablet — prescribing information · DailyMed, U.S. National Library of Medicine · retrieved 2026-08-12
  4. MOUNJARO (tirzepatide) injection — prescribing information · DailyMed, U.S. National Library of Medicine · retrieved 2026-08-12
  5. NCT07673900 — A Randomized, Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Epi/Intra-dermally Administered Semaglutide (VX-201) Compared to Subcutaneous Administration · ClinicalTrials.gov, U.S. National Library of Medicine · retrieved 2026-08-12
  6. NCT07539415 — A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers · ClinicalTrials.gov, U.S. National Library of Medicine · retrieved 2026-08-12
  7. The 500 Dalton rule for the skin penetration of chemical compounds and drugs (Exp Dermatol. 2000;9(3):165-9) · Bos JD, Meinardi MM — via PubMed · retrieved 2026-08-12
  8. Transdermal drug delivery (Nat Biotechnol. 2008;26(11):1261-8) · Prausnitz MR, Langer R — via PubMed · retrieved 2026-08-12
  9. Transdermal “Natural GLP-1” Dietary Supplements Violate Law and Place Patients at Risk (Ann Pharmacother. 2026 Aug) · Annals of Pharmacotherapy — via PubMed · retrieved 2026-08-12
  10. Enhanced Stability and Transdermal Delivery of Semaglutide Using an L-Arginine Based Dissolving Microneedle System (AAPS PharmSciTech. 2026 Jul 2) · AAPS PharmSciTech — via PubMed · retrieved 2026-08-12
  11. 21 U.S.C. § 321 — Definitions (subsection (ff), “dietary supplement”) · United States Code, 2023 Edition — via GovInfo · retrieved 2026-08-12
  12. PubChem Compound Summary — molecular weights of approved transdermal active ingredients · PubChem, U.S. National Library of Medicine · retrieved 2026-08-12
  13. PubChem Compound Summary for CID 76943386 — abaloparatide · PubChem, U.S. National Library of Medicine · retrieved 2026-08-13
  14. PubChem Compound Summary for CID 16133850 — teriparatide · PubChem, U.S. National Library of Medicine · retrieved 2026-08-13
  15. PubChem Compound Summary for CID 16132283 — glucagon · PubChem, U.S. National Library of Medicine · retrieved 2026-08-13
  16. PubChem Compound Summary for CID 56843331 — semaglutide · PubChem, U.S. National Library of Medicine · retrieved 2026-08-13
  17. PubChem Compound Summary for CID 166567236 — tirzepatide · PubChem, U.S. National Library of Medicine · retrieved 2026-08-13
  18. PubChem Compound Summary for CID 60857 — zolmitriptan · PubChem, U.S. National Library of Medicine · retrieved 2026-08-13
  19. NCT04064411 — Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis (phase 3, results posted) · ClinicalTrials.gov, U.S. National Library of Medicine · retrieved 2026-08-13
  20. NCT01011556 — A Study for the Transdermal Application of Teriparatide (phase 2, results posted) · ClinicalTrials.gov, U.S. National Library of Medicine · retrieved 2026-08-13
  21. NCT00489918 — Dose Ranging Study, Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women With Osteoporosis (phase 2, results posted) · ClinicalTrials.gov, U.S. National Library of Medicine · retrieved 2026-08-13
  22. NCT02745392 — Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine (phase 2/3, results posted) · ClinicalTrials.gov, U.S. National Library of Medicine · retrieved 2026-08-13
  23. openFDA drug adverse event endpoint — the FDA Adverse Event Reporting System (FAERS) · U.S. Food and Drug Administration · retrieved 2026-08-13
  24. CFSAN Adverse Event Reporting System (CAERS) — where reports about foods, cosmetics and dietary supplements are collected · U.S. Food and Drug Administration · retrieved 2026-08-13
  25. Warning Letter to FormPour, MARCS-CMS 722215 (2026-03-31) — “SMGT-GLT-1 Nano Microneedle Patch” offered as an unapproved new drug · U.S. Food and Drug Administration, Center for Drug Evaluation and Research · retrieved 2026-08-13

How we checked these details

Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewer

Reviewed 2026-08-13

Application numbers and approval dates on this page come from signed FDA approval letters, one per product, not from a press summary. The wider rules are in the sourcing methodology. If something here has gone stale, tell us at contact@healthspanledger.com.

Where these figures come from

Find the right guide before the detail

No guide is a ranked product list or a substitute for individual medical advice.

How well people handled Ozempic in its own trials

Ozempic and Wegovy are the same drug, and their labels report different numbers.

The letter FDA’s search misses, read from FDA’s published warning letters

0 letters come back when FDA’s own index is searched for the class as this letter spells it.

The GLP-1 microneedle patches page, figure by figure

3 further searches that returned nothing, each one printed so it can be re-run.

Dates, dockets and documents rather than commentary

Nothing is written in the future tense about a date that has already passed.

What each compound is, in one list

Class, approval status and strongest available source for every compound.

Questions readers ask

Do Ozempic patches really work?

Nothing sold as an Ozempic patch is an approved product, so no published result exists for one. No measurement in this page supports treating any adhesive patch as equal to the injection.

The one approved route without a needle shows the size of the problem. The oral tablet carries a built-in absorption helper, and even then only about 1% to 2% of the dose reaches the blood.

Does Ozempic come in a patch?

No. Two forms carry the Ozempic name in the federal listing and neither is worn on skin: the multi-dose pen and the single-dose prefilled syringe.

Four patches on sale say in their listings that they hold a GLP-1 drug, and none of them uses this brand name. No semaglutide product appears among the 157 approved transdermal applications either.

How long does it take to lose 20 pounds on Ozempic?

No cited source states how long it takes to reach a particular weight target. Ozempic is approved for adults with type 2 diabetes, not as a weight-loss product.

The trial reports average weight change at 72 weeks in adults with obesity. It studied semaglutide, not this specific product. The first four weeks use a 0.25 mg starting dose, not a dose intended to produce the final result.

Where can I buy Ozempatch?

No listing under that name turned up in the register this site keeps. That register holds ten patch listings, each read in full on the seller’s own page. No approved patch exists for either molecule, so no pharmacy dispenses one.

This site names no seller as a place to buy and links to none, by rule. Names with real search demand and no shop behind them are common here. Three were recorded that way, and one of the three has a domain that loads an empty storefront.